Tg Therapeutics (TGTX) Cost of Revenue (2021 - 2026)

Tg Therapeutics' Cost of Revenue history runs 6 years deep, the most recent figure standing at $33.5 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 115.62% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $118.7 million (up 144.28% YoY), while the FY2025 annual figure was $100.7 million, up 161.69% from the prior year.
• Cost of Revenue was $33.5 million for Q1 2026 at Tg Therapeutics, down from $38.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $38.1 million in Q4 2025 to a low of $2000.0 in Q3 2022.
• Historically, Cost of Revenue has averaged $12.5 million across 5 years, with a median of $8.3 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue surged 261700.0% in 2023, then surged 96.07% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $3000.0 in 2022, then soared by 261700.0% to $7.9 million in 2023, then soared by 96.07% to $15.4 million in 2024, then soared by 147.69% to $38.1 million in 2025, then fell by 12.14% to $33.5 million in 2026.
• The last three Cost of Revenue figures came in at $33.5 million (Q1 2026), $38.1 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.